Inotuzumab ozogamicin: a CD22 mAb–drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia

Overview of attention for article published in Drug Design, Development and Therapy, July 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (80th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

So far, Altmetric has seen 1 news story.

Follow Summary Cellectis is a biotech company focused on developing allogeneic CAR T-cell therapy, which uses donor T cells…